Drugs / Tegafur/gimeracil/oteracil potassium
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03662659 Background | Oct 2018 → Aug 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Bristol-Myers Squibb | Completed | Missed primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegafur/gimeracil/oteracil potassium | “Oxaliplatin + tegafur/gimeracil/oteracil potassium” NCT03662659 ↗ |